Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
AST-487
As low as
CHF 35.00
In stock
Only %1 left
AG-CR1-3745-M0011 mgCHF 35.00
AG-CR1-3745-M0055 mgCHF 110.00
AG-CR1-3745-M02525 mgCHF 290.00
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | AST487; NVP-AST-487 |
| Product Type | Chemical |
| Properties | |
| Formula |
C26H30F3N7O2 |
| MW | 529.6 |
| CAS | 630124-46-8 |
| Purity Chemicals | ≥95% |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO, DMF or ethanol. |
| Identity | Determined by 1H-NMR. |
| InChi Key | ODPGGGTTYSGTGO-UHFFFAOYSA-N |
| Smiles | CCN1CCN(CC2=C(C=C(NC(=O)NC3=CC=C(OC4=CC(NC)=NC=N4)C=C3)C=C2)C(F)(F)F)CC1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| Safety Data Sheet |
Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Scientific Background Information
Product Description
- AST487 is an inhibitor of RET (IC50 = 0.88µM), FLT3 (Ki = 0.52µM), KDR (IC50 = 0.17µM), c-Abl (IC50 = 0.02µM) and c-Kit (IC50 = 0.5µM).
- AST-487 has been shown to inhibit RET autophosphorylation and activation of downstream effectors and to prevent the growth of human thyroid cancer cell lines with activating mutations of RET but not of lines without RET mutations. In xenografts of NIH3T3 cells expressing oncogenic RET and of the MTC cell line TT in nude mice, AST-487 dose dependently inhibited tumor growth.
- AST-487, which selectively targets mutant FLT3 protein kinase activity, is also shown to override PKC412 resistance in vitro, and has significant antileukemic activity in an in vivo model of FLT3-ITD(+) leukemia. The combination of AST-487 with standard chemotherapeutic agents leads to enhanced inhibition of proliferation of mutant FLT3-expressing cells. AST-487 displays high selectivity and potency toward FLT3 as a molecular target, and could potentially be used to override drug resistance in AML.
Product-specific References
- The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells: N. Akeno-Stuart, et al.; Cancer Res. 67, 6956 (2007)
- Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells: E. Weisberg, et al.; Blood 112, 5161 (2008)
- Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison: E. Weisberg, et al.; Genes Cancer. 1, 1021 (2010)
- Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells: M.L. Gild, et al.; Endocr. Relat. Cancer 20, 659 (2013)
- Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts: E. Andreucci, et al.; Oncotarget 7, 80543 (2016)
You're in the Switzerland store. Not in Switzerland? Choose your country
You're in the Switzerland store (prices in CHF, shipping to Switzerland only). Ordering from another country? Please select it below.
Please note that not all products are available in every country store. Choose your country before starting the ordering process.
Country
Switzerland
United Kingdom
France
Germany
Austria
Italy
South Korea
United States
Argentina
Australia
Belgium
Bosnia and Herzegovina
Brazil
Canada
Chile
China
Colombia
Cyprus
Czech Republic
Denmark
Ecuador
Egypt
Estonia
Finland
Greece
Hong Kong
Hungary
India
Iran
Iraq
Ireland
Israel
Japan
Latvia
Lithuania
Luxembourg
Malaysia
Mexico
Netherlands
New Zealand
Norway
Pakistan
Peru
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Syria
Taiwan
Thailand
Turkey
Uruguay
Venezuela
Other Country
No country found




Download PDF